Histogen to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Business Update
04. März 2021 16:05 ET
|
Histogen Inc
SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
02. März 2021 08:00 ET
|
Histogen Inc
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
16. Februar 2021 08:00 ET
|
Histogen Inc
HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in U.S. SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:...
Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration
19. Januar 2021 16:05 ET
|
Histogen Inc
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
06. Januar 2021 08:00 ET
|
Histogen Inc
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces Closing of $14.0 Million Upsized Public Offering
05. Januar 2021 16:05 ET
|
Histogen Inc
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen Announces Pricing of $14.0 Million Upsized Public Offering
30. Dezember 2020 22:25 ET
|
Histogen Inc
SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen Announces Filing an Investigational New Drug Application for HST-003
17. Dezember 2020 08:00 ET
|
Histogen Inc
Phase 1/2 Trial Initiation for Knee Cartilage Regeneration Anticipated in First Quarter 2021 $2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical Development SAN...
Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
01. Dezember 2020 08:00 ET
|
Histogen Inc
HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Week 26 Final Study Results...
Histogen Announces Closing of $4.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
16. November 2020 16:05 ET
|
Histogen Inc
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...